Abstracts tagged "patient outcomes"

Abstract Number: 3151 • 2015 ACR/ARHP Annual Meeting
Validation of Patient-Reported Outcomes Measurement Information System (PROMIS®) Modules for Use in Childhood-Onset Lupus
Jordan T. Jones¹, Janet Wootton², Jun Ying³, Brianna Liberio⁴, Jiha Lee⁵, Adam Carle⁶, Laura Schanberg² and Hermine I. Brunner⁶, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatrics, Duke Medical Center, Durham, NC, ³University of Cincinnati, Cincinnati, OH, ⁴University of Cincinnati College of Medicine, Cincinnati, OH, ⁵Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Childhood-onset lupus (cSLE) has a substantial negative impact on health-related quality of life (HRQoL). Patient-reported outcomes (PROs) that accurately assess HRQoL and are responsive…
Abstract Number: 658 • 2015 ACR/ARHP Annual Meeting
Health Related Quality of Life in Psoriatic Arthritis from the Perspective of People Living with the Condition
Ana-Maria Orbai^1,2, Suzanne Grieb³, Clifton Bingham⁴, Michelle Jones⁴, Grazyna Purwin⁵ and Katherine Clegg-Smith⁶, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Bayview Medical Center, Center for Child and Community Health Research, Baltimore, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Johns Hopkins Arthritis Center, Baltimore, MD, ⁶Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Background/Purpose: Psoriatic arthritis (PsA) is a complex inflammatory disease with variable phenotype affecting skin, joints, ligaments/tendons, nails, and the spine. Heterogeneity of clinical manifestations complicates…
Abstract Number: 677 • 2015 ACR/ARHP Annual Meeting
Satisfaction in Psoriatic Arthritis Patients Despite Active Joint Disease
Daniel E. Furst¹, Emma Sullivan², James Pike³, James Piercy⁴, Jacqueline Palmer⁵ and Vivian Herrera⁵, ¹Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Adelphi Real World, Manchester, United Kingdom, ³Statistics, Adelphi Real World, Macclesfield, United Kingdom, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic immune-mediated condition with multiple manifestations; joint inflammation with subsequent joint damage is a key component. Across a number…
Abstract Number: 679 • 2015 ACR/ARHP Annual Meeting
Patients with Psoriatic Arthritis and Oligoarthritic Subtype Report Higher Disease Burden Than Patients with a Polyarthritic Pattern – Data from the German Collaborative Arthritis Centres
Dörte Huscher¹, Katinka Albrecht², Sascha Bischoff², Katja Thiele², Frank Behrens³, Kathrin Fischer⁴, Ulrich von Hinüber⁵, Susanna Späthling-Mestekemper⁶, Siegfried Wassenberg⁷ and Angela Zink¹, ¹German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ⁴Praxis fuer Innere Medizin, Aerztehaus Schoenwalde, Greifswald, Germany, ⁵Practice-based rheumatologist, Hildesheim, Germany, ⁶Practice-based rheumatologist, München, Germany, ⁷Rheumaklinik, Themistocles Gluck hospital - Rheumazentrum Ratingen, Ratingen, Germany
Background/Purpose: Psoriatic arthritis (PsA) divides into different subtypes, of which polyarthritis and spondylitis would be expected with the highest disease severity. We compared disease burden…
Abstract Number: 682 • 2015 ACR/ARHP Annual Meeting
Misalignment Between Physician and Patient Satisfaction with Current Psoriatic Arthritis Treatment
Daniel E. Furst¹, Emma Sullivan², James Pike³, James Piercy⁴, Jacqueline Palmer⁵ and Vivian Herrera⁵, ¹Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Adelphi Real World, Manchester, United Kingdom, ³Statistics, Adelphi Real World, Macclesfield, United Kingdom, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic immune related condition affecting the joints and commonly occurs alongside psoriasis. Well-established physician patient relationships are instrumental to…
Abstract Number: 1746 • 2015 ACR/ARHP Annual Meeting
Patient’s Ability of Coping Is Influencing the Correlation Between Clinical and Ultrasonographic Evidence of Disease Activity in Psoriatic Arthritis
Brigitte Michelsen¹, Andreas P Diamantopoulos^1,2, Hilde Berner Hammer³, Dag Magnar Soldal⁴, Arthur Kavanaugh⁵ and Glenn Haugeberg^1,6,7, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁵University of California, San Diego School of Medicine, LaJolla, CA, ⁶Rheumatology, Martina Hansens Hospital, Gjettum, Norway, ⁷Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: Coping may be defined as the set of adaptive processes a patient uses to live well with aspects of disease such as pain. Coping…
Abstract Number: 1974 • 2015 ACR/ARHP Annual Meeting
Do Patients with Giant Cell Arteritis Meet the 2011 United Kingdom Department of Health Guidance on Physical Activity?
Joanna Robson¹, Karolina Lada², Anne Miller³, Wilby Williamson¹, Julia Newton² and Raashid Luqmani⁴, ¹Rheumatology, University of Oxford, Oxford, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³Nuffield Orthopaedic Center, Oxford., Oxford, United Kingdom, ⁴Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Physical inactivity is the fourth leading risk factor for global mortality accounting for 6% of deaths. Patients with giant cell arteritis (GCA) are at…
Abstract Number: 2327 • 2015 ACR/ARHP Annual Meeting
Documentation of Clinical Improvement in Patient with Polymyalgia Rheumatica According to MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data): Longitudinal Analysis from Routine Care
Isabel Castrejón¹, Annie Huang¹, Sarah L. Everakes², Ailda Nika¹, Winston Sequeira¹ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Internal Medicine, Rush University Medical Center, Chicago, IL
Background/Purpose: RAPID3 is an index found on the MDHAQ, which is effective in rheumatoid arthritis (RA) clinical trials and clinical care (1). MDHAQ/RAPID3 also is…
Abstract Number: 2493 • 2015 ACR/ARHP Annual Meeting
Improvement of Disease Activity and Quality of Care in a Cohort of Rheumatoid Arthritis Patients Treated with Conventional Dmard Therapy Under Treat to Target Recommendations and a Model of Patient-Centered Care
Pedro Ivan Santos-Moreno¹, Ginna Saavedra², Rosana Ramirez², Laura Villarreal², Ana Bolena Cardozo², Vanessa Giraldo², Paola Martinez², Adriana Sanchez², Merle Sanchez², Danny Gomez² and Juan Manuel Bello², ¹Rheumatology, Biomab, Center for Rheumatoid Arthritis., Bogota, Colombia, ²Rheumatology, Biomab, Center for Rheumatoid Arthritis, Bogota, Colombia, Bogota, Colombia
Background/Purpose: Treat to Target (T2T) strategy becomes from the need to develop therapeutic targets and tools to achieve defined outcomes in rheumatoid arthritis (RA). Moreover,…
Abstract Number: 2640 • 2015 ACR/ARHP Annual Meeting
Factors Influencing Treatment Adjustments in RA Patients – Biologic DMARD Treatment Start and Options
Peter C. Taylor¹, Emma Sullivan², Robert Wood³, James Piercy³, Rieke Alten⁴, Juan J Gomez-Reino⁵, Philippe Bertin⁶, Roberto Caporali⁷, Radu Vasilescu⁸, Dean Spurden⁹ and Jose Alvir¹⁰, ¹Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, ²Adelphi Real World, Manchester, United Kingdom, ³Adelphi Real World, Macclesfield, United Kingdom, ⁴Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁵Desarmen of Rheumatology, Unit Hospital Clinico Universitario, Santiago, Spain, ⁶Rheumatology, CHU Dupuytren, Limoges, France, ⁷University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁸Medical Affairs, Pfizer Inc, Brussels, Belgium, ⁹Pfizer Inc, Tadworth, United Kingdom, ¹⁰Global Health and Value, Pfizer Inc, New York, NY
Background/Purpose: Current recommendations for pharmacologic management of rheumatoid arthritis (RA) advise dose titration or switching treatment if goals of remission or low disease activity are…
Abstract Number: 2641 • 2015 ACR/ARHP Annual Meeting
Correlation of Rheumatologists’ Perceptions of RA Severity with Observed Disease Activity, Patient Impact and Treatment Patterns
Peter C. Taylor¹, Juan J Gomez-Reino², Roberto Caporali³, Rieke Alten⁴, Philippe Bertin⁵, Emma Sullivan⁶, Robert Wood⁷, James Piercy⁷, Radu Vasilescu⁸, Dean Spurden⁹ and Jose Alvir¹⁰, ¹Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, ²Desarmen of Rheumatology, Unit Hospital Clinico Universitario, Santiago, Spain, ³University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁴Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁵Rheumatology, CHU Dupuytren, Limoges, France, ⁶Adelphi Real World, Manchester, United Kingdom, ⁷Adelphi Real World, Macclesfield, United Kingdom, ⁸Medical Affairs, Pfizer Inc, Brussels, Belgium, ⁹Pfizer Inc, Tadworth, United Kingdom, ¹⁰Global Health and Value, Pfizer Inc, New York, NY
Background/Purpose: Efforts have been made in recent years to standardize the clinical assessment of RA patients with increased focus on objective measures, such as the…
Abstract Number: 2318 • 2014 ACR/ARHP Annual Meeting
Increasing Rates of Remission in Juvenile Idiopathic Arthritis through a Quality Improvement Learning Network – the Pediatric Rheumatology Care and Outcomes Improvement Network
Esi M. Morgan DeWitt¹, Stacy P. Ardoin², C. April Bingham³, Beth S. Gottlieb⁴, Ronald Laxer⁵, Nancy Griffin⁶, Jesse Pratt⁷, Anne Paul⁸, Daniel Lovell⁹, Judyann C. Olson¹⁰, Murray H. Passo¹¹, Jennifer E. Weiss¹², Tzielan C. Lee¹³, Sheetal S. Vora¹⁴, Melissa M. Hazen¹⁵ and Peter Margolis¹⁶, ¹Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, ³Penn State Hershey Children's Hospital, Hershey, PA, ⁴Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁵Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, ¹⁰Medical College of Wisconsin, Milwaukee, WI, ¹¹Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ¹²Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹³Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ¹⁴University of North Carolina Chapel Hill, Chapel Hill, NC, ¹⁵Division of Immunology, Boston Children's Hospital, Boston, MA, ¹⁶Clinical Effectiveness, Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) since 2011 has used quality improvement (QI) methods, chronic illness care model interventions, and a…
Abstract Number: 1407 • 2014 ACR/ARHP Annual Meeting
Low HAQ and Pain Predict Patient Perceived Remission in Rheumatoid Arthritis Patients Receiving MTX or Anti-TNF-Alpha Treatment
Paul Studenic¹, Josef Smolen² and Daniel Aletaha¹, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine 3, Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose The induction of remission is the primary target of RA therapy. Failing to achieve the patient global estimate of disease activity criterion (PGA
Abstract Number: 110 • 2014 ACR/ARHP Annual Meeting
Use of Smartphones in Collecting Patient Reported Outcomes: Can Passively-Collected Behavior Determine Rheumatic Disease Activity? Early Results from a Nation-Wide Pilot Study
Kaleb Michaud^1,2, Sofia Pedro¹, Rebecca Schumacher¹, Karim Wahba³ and Sai Moturu³, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³ginger.io, San Francisco, CA
Background/Purpose Rheumatoid arthritis (RA) and other rheumatic diseases (RD) are associated with depression, fatigue, and disturbed sleep, symptoms that often impact behavior. Many smartphone apps…
Abstract Number: 108 • 2014 ACR/ARHP Annual Meeting
Patient Reported Outcomes Following Total Knee Arthroplasty in Rheumatoid Arthritis and Osteoarthritis
Anand Dusad¹, Sofia Pedro², Kevin Garvin³, Curtis Hartman⁴, James O'Dell⁵, Ted R. Mikuls⁵ and Kaleb Michaud⁶, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Orthopaedic Surgery, University of Nebraska Medical Center, Omaha, NE, ⁴Orthopaedic Surgery and Rehabilitation, University of Nebraska Medical Center, Omaha, NE, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of Nebraska Medical Center and National Data Bank, Omaha, NE
Background/Purpose: Due to the progressive and debilitating nature of knee arthritis, total knee arthroplasty (TKA) is the ultimate outcome. TKA is an effective surgical intervention…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].